Kisspeptin
Kisspeptin (KISS-1) is the absolute primordial trigger of the mammalian Hypothalamic-Pituitary-Gonadal (HPG) axis, effectively acting as the upstream master switch for human reproduction and endocrinology. Distinct from hCG or Enclomiphene, it is deployed in elite integrative endocrinology to aggressively upregulate endogenous testosterone production, reverse hypogonadism, and preserve massive gonadal volume without inducing estrogenic side effects or risking HPTA shutdown. It represents the cleanest, most physiologically natural method of restoring a suppressed hormonal baseline.
Quick Stats
Scientific Data
Mechanism of Action
Kisspeptin is a neuropeptide encoded by the KISS1 gene that acts as the master upstream regulator of the reproductive hormone cascade. It activates GPR54 (KISS1R) receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release which drives LH and FSH secretion.
Kisspeptin sits at the very top of the HPG axis — above GnRH itself. Loss-of-function mutations in KISS1 or GPR54 cause hypogonadotropic hypogonadism (failure to enter puberty). Exogenous kisspeptin is studied as a diagnostic tool for reproductive disorders and as a therapeutic for functional hypothalamic amenorrhea (FHA), male hypogonadism, and polycystic ovary syndrome (PCOS). Because it acts upstream of GnRH, it can restart the entire reproductive cascade from the top down.
Source: PMID: 16140907
Background & History
Kisspeptin is a 54-amino-acid peptide encoded by the KISS1 gene, first identified in 1996 as a metastasis suppressor by Danny Welch at Pennsylvania State University. Its role as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis was discovered in 2003 independently by multiple groups who found KISS1 receptor mutations caused hypogonadotropic hypogonadism. Kisspeptin neurons directly activate GnRH neurons — it is upstream of GnRH in the reproductive endocrine hierarchy. It integrates metabolic status, stress, and environmental cues to regulate fertility and sexual function.
Research Use Cases
- ✓Hypogonadotropic hypogonadism: restoring LH/FSH/testosterone naturally
- ✓Male sexual arousal via limbic system KISS1R activation
- ✓HPG axis restart after exogenous testosterone suppression
- ✓Female fertility: stimulating ovulation in hypothalamic amenorrhea
- ✓Research: endocrine disruption assessment (clinical probe)
Dosing Protocol
| Typical Dose | 100-500 mcg/dose |
| Frequency | 1-2× daily |
| Half-Life | ~28 minutes |
| Common Vial Sizes | 5 mg |
Dosing Protocols
Diagnostic / Research
Therapeutic Research
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 100–500 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 77 mcg | 231 mcg | 386 mcg |
| 140 lb(63 kg) | 90 mcg | 270 mcg | 450 mcg |
| 160 lb(73 kg) | 104 mcg | 313 mcg | 521 mcg |
| 180 lb(82 kg) | 117 mcg | 351 mcg | 586 mcg |
| 200 lb(91 kg) | 130 mcg | 390 mcg | 650 mcg |
| 220 lb(100 kg) | 143 mcg | 429 mcg | 714 mcg |
| 250 lb(113 kg) | 161 mcg | 484 mcg | 807 mcg |
💉 For exact syringe units based on your vial concentration, use the Kisspeptin Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Reproductive Endocrinology
ModerateStrong evidence for LH/FSH stimulation. In clinical trials for FHA and hypogonadism.
HPG Axis Restart / PCT
LowStudied for post-cycle testosterone restoration. Experimental — less established than triptorelin or gonadorelin for PCT.
Reconstitution Example
Safety & Considerations
Endogenous neuropeptide with clinical trial safety data. Short half-life limits systemic exposure. May cause transient facial flushing. Chronic pulsatile delivery requires IV access — not practical outside clinical research. Not yet FDA-approved for therapeutic use.
Regulatory & Legal Status
Competitive athletes subject to anti-doping controls should not use Kisspeptin.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Kisspeptin pulses are required for efficacy — continuous GnRH output leads to downregulation. Exogenous testosterone suppresses kisspeptin neurons (negative feedback) — less effective while on TRT. Elevated estrogen also provides negative feedback. Leptin deficiency blunts kisspeptin response (anorexia, extreme caloric restriction).
Synergies & Common Stacks
Kisspeptin drives GnRH neuron firing; Gonadorelin replaces the GnRH signal directly at the pituitary. Together offer complete HPG axis stimulation cascade.
Kisspeptin addresses the hormonal axis (LH, testosterone, ovulation); PT-141 addresses the neurological arousal dimension. Comprehensive sexual health protocol.
Featured In Clinical Protocols
Sexual Health & Libido Restoration
Regain robust libido, erectile quality, and central nervous system desire through melanocortin and Kisspeptin receptor targeting.
Perimenopause & Menopause Optimization
Comprehensive stack combining peptides and targeted supplements to restore hormonal signaling, alleviate vasomotor symptoms, combat metabolic slowdown, and restore libido.
Dosing Quick Reference
Frequently Asked Questions
How is Kisspeptin different from Gonadorelin?▼
Can Kisspeptin be used for PCT?▼
References
- Dhillo WS et al. “"Kisspeptin-10 and LH secretion in humans".” Journal of Clinical Endocrinology & Metabolism (2005). PMID: 16131585
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code